Valeria Ricotti1, William P L Mandy2, Mariacristina Scoto1, Marika Pane3, Nicolas Deconinck4,5, Sonia Messina6, Eugenio Mercuri1,3, David H Skuse2, Francesco Muntoni1. 1. Dubowitz Neuromuscular Centre, UCL Institute of Child Health, London, UK. 2. Behavioural and Brain Sciences Unit, UCL Institute of Child Health, London, UK. 3. Department of Paediatric Neurology, Catholic University, Rome, Italy. 4. Department of Paediatric Neurology, NMRC, Universitair Ziekenhuis Gent, Gent, Belgium. 5. Paediatric Neurology Department, Hôpital Universitaire des Enfants Reine Fabiola, Universite Libre de Bruxelles, Brussels, Belgium. 6. Department of Neurosciences and Nemo Sud Clinical Centre, University of Messina, Messina, Italy.
Abstract
AIM: Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders. The aim of the study was to characterize the DMD neuropsychiatric profile fully and to explore underlying genotype/phenotype associations. METHOD: One hundred and thirty males with DMD (mean age 9y 10mo, range 5-17y) in four European centres were included and completed IQ assessment and a neurodevelopmental-screening questionnaire. Of these, 87 underwent comprehensive neuropsychiatric assessment using structured diagnostic interview and parent-reported questionnaires. RESULTS: The overall mean score on the neurodevelopmental questionnaire was significantly abnormal compared with the general population of children (p<0.001). On average, intelligence was below the population mean, with intellectual disability observed in 34 males (26%). Autistic spectrum disorder was identified in 18 (21%), hyperactivity in 21 (24%), and inattention in 38 (44%). Clinical levels of internalizing and externalizing problems were observed in 21 (24%) and 13 (15%) respectively. Over a third of males scored more than two measures of emotional, behavioural, or neurodevelopmental problems. Males with mutations at the 3' end of the DMD gene affecting all protein isoforms had higher rates of intellectual disability and clusters of symptoms. INTERPRETATION: Males with DMD are at very high risk of neuropsychiatric disturbance, and this risk appears to increase with mutations at the 3' end of the gene. Patterns of symptom clusters suggest a DMD neuropsychiatric syndrome, which may require prompt evaluation and early intervention.
AIM: Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders. The aim of the study was to characterize the DMD neuropsychiatric profile fully and to explore underlying genotype/phenotype associations. METHOD: One hundred and thirty males with DMD (mean age 9y 10mo, range 5-17y) in four European centres were included and completed IQ assessment and a neurodevelopmental-screening questionnaire. Of these, 87 underwent comprehensive neuropsychiatric assessment using structured diagnostic interview and parent-reported questionnaires. RESULTS: The overall mean score on the neurodevelopmental questionnaire was significantly abnormal compared with the general population of children (p<0.001). On average, intelligence was below the population mean, with intellectual disability observed in 34 males (26%). Autistic spectrum disorder was identified in 18 (21%), hyperactivity in 21 (24%), and inattention in 38 (44%). Clinical levels of internalizing and externalizing problems were observed in 21 (24%) and 13 (15%) respectively. Over a third of males scored more than two measures of emotional, behavioural, or neurodevelopmental problems. Males with mutations at the 3' end of the DMD gene affecting all protein isoforms had higher rates of intellectual disability and clusters of symptoms. INTERPRETATION: Males with DMD are at very high risk of neuropsychiatric disturbance, and this risk appears to increase with mutations at the 3' end of the gene. Patterns of symptom clusters suggest a DMD neuropsychiatric syndrome, which may require prompt evaluation and early intervention.
Authors: Maria Chahrour; Brian J O'Roak; Emanuela Santini; Rodney C Samaco; Robin J Kleiman; M Chiara Manzini Journal: J Neurosci Date: 2016-11-09 Impact factor: 6.167
Authors: David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; Mary K Colvin; Linda Cripe; Adrienne R Herron; Annie Kennedy; Kathi Kinnett; James Naprawa; Garey Noritz; James Poysky; Natalie Street; Christina J Trout; David R Weber; Leanne M Ward Journal: Lancet Neurol Date: 2018-02-02 Impact factor: 44.182
Authors: Mathula Thangarajh; Jos Hendriksen; Michael P McDermott; William Martens; Kimberly A Hart; Robert C Griggs Journal: Neurology Date: 2019-10-08 Impact factor: 9.910
Authors: Maqsood Ahmed; Leandro N Marziali; Ernest Arenas; M Laura Feltri; Charles Ffrench-Constant Journal: Development Date: 2019-08-29 Impact factor: 6.868